Loading clinical trials...
Loading clinical trials...
Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
Conditions
Locations
40
Italy
Istituto Oncologico del Mediterraneo
Catania, Catania, Italy
Policlinico Maggiore
Milan, Italy, Italy
Ospedale San Gennaro
Naples, Italy, Italy
Azienda Ospedaliera V. Cervello
Palermo, Italy, Italy
Azienda Ospedaliera "Bianchi Melacrino Morelli"
Reggio Calabria, Italy, Italy
Presidio Ospedaliero - Unità Complessa Ematologia
Treviso, Italy, Italy
Start Date
May 1, 2010
Completion Date
June 1, 2011
Last Updated
March 6, 2013
NCT06667687
NCT05618925
NCT05623982
NCT03314974
NCT06014073
NCT04586478
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions